CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, announced today it has received the 2024 MedTech Breakthrough Award ...
Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI (TM) algorithm for cardiac amyloidosis (CA) -- the first and only cleared ...
Artificial intelligence (AI)-based algorithms that use electrocardiogram (ECG) data have high accuracy in predicting ...
Real-world evidence to be presented at the American College of Cardiology Scientific Session 2026 highlights impact of Viz HCM, developed as part of a multi-year agreement with Bristol Myers Squibb, ...
An artificial intelligence (AI) algorithm paired with the single-lead electrocardiogram (ECG) sensors on a smartwatch accurately diagnosed structural heart diseases, such as weakened pumping ability, ...
Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled software-as-a-medical-device ...
Clinicians rely daily on electrocardiograms (ECG) to detect common cardiovascular conditions, but accurate diagnoses require high levels of expertise. In a new study that reviewed nearly 1 million ...
Anumana’s innovative AI algorithms recognized for their transformative potential in cardiology - the first of which is now commercially available “At Anumana, we are committed to developing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results